心血管疾病中的循环RNA:诊断和治疗的范式转变
Rajesh Parsanathan1, Sredha Sunil1, Rishaba Byju1
1Department of Biotechnology, School of Integrative Biology, Central University of Tamil Nadu, Neelakudi, Thiruvarur 610 005, Tamil Nadu, India.
Life sciences
|July 23, 2025
概括
循环RNAs (circRNAs) 在诊断和治疗心血管疾病 (CVD) 方面表现有前途. 这些稳定的分子为心肌病和动脉样硬化等疾病提供了新的生物标志物和治疗点.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 心血管疾病 (CVD) 是全球主要的死亡原因,需要创新的诊断和治疗策略.
- 循环RNAs (circRNAs) 正因其稳定性和特定表达模式而成为各种生物过程中的关键调节者.
研究的目的:
- 审查circRNAs在心血管疾病发病过程中的作用.
- 探索circRNAs在心血管疾病管理中的诊断潜力和治疗应用.
主要方法:
- 对调查心血管疾病中circRNAs的研究进行文献综述.
- 在包括心肌病,动脉样硬化,心肌梗塞和高血压在内的疾病中分析circRNA机制.
主要成果:
- 特定的circRNAs (例如circHIPK3,circFndc3b,circANRIL) 通过调节细胞增大,炎症和细胞增殖,与心血管疾病的发病有关.
- 循环RNAs显示出潜在的生物流体中的生物标志物,用于诸如心肌损伤等疾病.
- 治疗策略包括反感性寡核酸沉默和提供保护性circRNA模拟剂.
结论:
- circRNAs代表了对心血管疾病有前途的生物标志物和治疗点.
- 需要进一步的研究来克服组织特异性传递的挑战,并了解临床转化中的类效应.
相关概念视频
Coronary Artery Disease I: Introduction
59
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
59
Cardiomyopathy IV: Restrictive Cardiomyopathy
35
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
35
Cardiovascular Drugs: Classification based on Therapeutic Indications
3.2K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.2K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
217
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
217
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
65
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
65
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
693
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
693


